04 · 21 proprietary layers
Layer 8 of 21 · Tumour behaviour
ResistMap Resistance mechanisms and bypass routes.
Why it's needed
What resistance-related mechanisms or alternate pathways may warrant consideration?
What it draws on
3 of 8 evidence domains.
What it produces
Resistance-related signals or hypotheses, and supporting context for clinician review.
Why it's essential
Layer 8 of 21.
1 · What it does
What ResistMap does
Tumours can become less sensitive to a treatment through changes in the drug's target or by switching to alternative signalling routes (bypass pathways). ResistMap is intended to surface findings the evidence associates with resistance, so they can be considered in context.
2 · Scientific question
The question it addresses
What resistance-related mechanisms or alternate pathways may warrant consideration?
Intended function
Present supported resistance-associated findings and the evidence connecting them to the tumour context.
3 · Data inputs and required context
What it draws on
- 01 Molecular & genomic
- 06 Treatment exposure
- 08 Evidence ecosystem
Molecular findings, prior and current therapies, and the resistance literature.
4 · Scientific basis
The science behind it
Scientific basis
Resistance-associated evidence includes secondary alterations in the drug target, activation of parallel pathways and changes in cell lineage. The supporting evidence ranges from clinical cohorts to laboratory models, and its strength varies widely.
5 · Output and evidence sources
What it produces
Main output
Resistance-related signals or hypotheses, and supporting context for clinician review.
Output type
- Evidence-linked interpretation. Connects a finding to published or curated evidence, which has a source and a date.
- Computational inference. Estimated by analysis of available data rather than measured directly.
6 · Why it\u2019s essential
How it powers the Twin
Read alongside AccessMatch in the treatment-options section, and revisited when treatment changes or new findings arrive.
Report section
Capability
ExploreReview treatment-relevant evidence, resistance-related findings and potential trial matches.
7 · Why it\u2019s needed
What it changes — for doctors, patients and researchers
Clinicians
Resistance-associated findings with the strength and type of supporting evidence shown.
Doctor & Clinical TeamPatients & caregivers
Explains why a treatment that once worked may be reconsidered, and why new tests may be discussed.
Patient & Caregiver8 · Dependencies and limitations
Limitations
- A plausible mechanism is not proof that resistance is present, or that a specific treatment will fail.
- Laboratory evidence of resistance may not translate to patients.
9 · Review and uncertainty
How the output is handled
Output status
An AI-assisted analytical output presented as structured findings for clinician review. It becomes part of a report only after the treating oncologist has reviewed and signed it.
How uncertainty is communicated
Each signal is tagged with its evidence type (clinical, preclinical or inferred) and how directly it applies to the case.
10 · Claim boundary
What this layer does not establish
It does not establish that the tumour is resistant to a given therapy.
The treating oncologist owns every decision. Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board.
KPCIRC sign-off process